Page 1 | Search Results | Diabetes Care | American Diabetes Association

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128–2136

Geremia B. Bolli, Francesca Porcellati, Paola Lucidi, Carmine G. Fanelli

Diabetes Care 2021;44(3):e59–e60

https://doi.org/10.2337/dc20-2575

Published: 11 February 2021

View article titled, Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128–2136

Journal Articles

Pharmacokinetic and Pharmacodynamic Head-to-Head Comparison of Clinical, Equivalent Doses of Insulin Glargine 300 units · mL⁻¹ and Insulin Degludec 100 units · mL⁻¹ in Type 1 Diabetes

Paola Lucidi, Paola Candeloro, Patrizia Cioli, Anna Marinelli Andreoli, Chiara Pascucci, Angela Gambelunghe, Geremia B. Bolli, Carmine G. Fanelli, Francesca Porcellati

Diabetes Care 2021;44(1):125–132

https://doi.org/10.2337/dc20-1033

Published: 10 November 2020

View article titled, Pharmacokinetic and Pharmacodynamic Head-to-Head Comparison of Clinical, Equivalent Doses of Insulin Glargine 300 units · mL<sup>−1</sup> and Insulin Degludec 100 units · mL<sup>−1</sup> in Type 1 Diabetes

Journal Articles

Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes

Francesca Porcellati, Paola Lucidi, Paola Candeloro, Patrizia Cioli, Anna Marinelli Andreoli, Gianluca Curti, Geremia B. Bolli, Carmine G. Fanelli

Diabetes Care 2019;42(1):85–92

https://doi.org/10.2337/dc18-0706

Published: 10 October 2018

View article titled, Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes

Includes: Supplementary data

Journal Articles

How to Accurately Establish Pharmacokinetics/Pharmacodynamics of Long-Acting Insulins in Humans: Relevance to Biosimilar Insulins

Francesca Porcellati, Paola Lucidi, Geremia B. Bolli, Carmine G. Fanelli

Diabetes Care 2015;38(12):2237–2240

https://doi.org/10.2337/dc15-1848

Published: 19 November 2015

View article titled, How to Accurately Establish Pharmacokinetics/Pharmacodynamics of Long-Acting Insulins in Humans: Relevance to Biosimilar Insulins

Journal Articles

Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection

Paola Lucidi, Francesca Porcellati, Anna Marinelli Andreoli, Ilaria Carriero, Paola Candeloro, Patrizia Cioli, Geremia B. Bolli, Carmine G. Fanelli

Diabetes Care 2015;38(12):2204–2210

https://doi.org/10.2337/dc15-0801

Published: 10 September 2015

View article titled, Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection

Includes: Supplementary data

Journal Articles

Low Levels of Unmodified Insulin Glargine in Plasma of People With Type 2 Diabetes Requiring High Doses of Basal Insulin

Paola Lucidi, Francesca Porcellati, Hannele Yki-Järvinen, Matthew C. Riddle, Paola Candeloro, Anna Marinelli Andreoli, Geremia B. Bolli, Carmine G. Fanelli

Diabetes Care 2015;38(7):e96–e97

https://doi.org/10.2337/dc14-2662

Published: 11 June 2015

View article titled, Low Levels of Unmodified Insulin Glargine in Plasma of People With Type 2 Diabetes Requiring High Doses of Basal Insulin

Journal Articles

Pharmacokinetics and Pharmacodynamics of Insulin Glargine Given in the Evening as Compared With in the Morning in Type 2 Diabetes

Francesca Porcellati, Paola Lucidi, Patrizia Cioli, Paola Candeloro, Anna Marinelli Andreoli, Stefania Marzotti, Maura Ambrogi, Geremia B. Bolli, Carmine G. Fanelli

Diabetes Care 2015;38(3):503–512

https://doi.org/10.2337/dc14-0649

Published: 18 December 2014

View article titled, Pharmacokinetics and Pharmacodynamics of Insulin Glargine Given in the Evening as Compared With in the Morning in Type 2 Diabetes

Includes: Supplementary data

Journal Articles

Thirty Years of Research on the Dawn Phenomenon: Lessons to Optimize Blood Glucose Control in Diabetes

Francesca Porcellati, MD, PHD, Paola Lucidi, MD, PHD, Geremia B. Bolli, MD, Carmine G. Fanelli, MD, PHD

Diabetes Care 2013;36(12):3860–3862

https://doi.org/10.2337/dc13-2088

Published: 13 November 2013

View article titled, Thirty Years of Research on the Dawn Phenomenon: Lessons to Optimize Blood Glucose Control in Diabetes

Journal Articles

Metabolism of Insulin Glargine After Repeated Daily Subcutaneous Injections in Subjects With Type 2 Diabetes

Paola Lucidi, MD, Francesca Porcellati, MD, Paolo Rossetti, MD, Paola Candeloro, PHD, Anna Marinelli Andreoli, MD, Patrizia Cioli, RD, Annke Hahn, PHD, Ronald Schmidt, PHD, Geremia B. Bolli, MD, Carmine G. Fanelli, MD

Diabetes Care 2012;35(12):2647–2649

https://doi.org/10.2337/dc12-0271

Published: 14 November 2012

View article titled, Metabolism of Insulin Glargine After Repeated Daily Subcutaneous Injections in Subjects With Type 2 Diabetes

Includes: Supplementary data

Journal Articles

Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes Mellitus

Francesca Porcellati, MD, Paola Lucidi, MD, Paolo Rossetti, MD, Paola Candeloro, PHD, Anna Marinelli Andreoli, MD, Stefania Marzotti, MD, Patrizia Cioli, RD, Geremia B. Bolli, MD, Carmine G. Fanelli, MD

Diabetes Care 2011;34(12):2521–2523

https://doi.org/10.2337/dc11-1064

Published: 14 November 2011

View article titled, Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes Mellitus

Includes: Supplementary data

Journal Articles

Pharmacokinetics and Pharmacodynamics of Therapeutic Doses of Basal Insulins NPH, Glargine, and Detemir After 1 Week of Daily Administration at Bedtime in Type 2 Diabetic Subjects: A randomized cross-over study

Paola Lucidi, MD, Francesca Porcellati, MD, Paolo Rossetti, MD, Paola Candeloro, PHD, Patrizia Cioli, RD, Stefania Marzotti, MD, Anna Marinelli Andreoli, MD, Raffaela Fede, MD, Geremia B. Bolli, MD, Carmine G. Fanelli, MD

Diabetes Care 2011;34(6):1312–1314

https://doi.org/10.2337/dc10-1911

Published: 20 May 2011

View article titled, Pharmacokinetics and Pharmacodynamics of Therapeutic Doses of Basal Insulins NPH, Glargine, and Detemir After 1 Week of Daily Administration at Bedtime in Type 2 Diabetic Subjects: <subtitle>A randomized cross-over study</subtitle>

Includes: Supplementary data

Journal Articles

Pivotal Role of Timely Basal Insulin Replacement After Metformin Failure in Sustaining Long-Term Blood Glucose Control at a Target in Type 2 Diabetes

Geremia B. Bolli, MD, Paola Lucidi, MD, Francesca Porcellati, MD, Carmine G. Fanelli, MD

Diabetes Care 2011;34(Supplement_2):S220–S224

https://doi.org/10.2337/dc11-s224

Published: 22 April 2011

View article titled, Pivotal Role of Timely Basal Insulin Replacement After Metformin Failure in Sustaining Long-Term Blood Glucose Control at a Target in Type 2 Diabetes

Journal Articles

Hyperglycemia-Induced Platelet Activation in Type 2 Diabetes Is Resistant to Aspirin but Not to a Nitric Oxide–Donating Agent

Paolo Gresele, MD, PHD, Stefania Marzotti, MD, Giuseppe Guglielmini, PHD, Stefania Momi, PHD, Silvia Giannini, PHD, Pietro Minuz, MD, Paola Lucidi, MD, Geremia B. Bolli, MD, PHD

Diabetes Care 2010;33(6):1262–1268

https://doi.org/10.2337/dc09-2013

Published: 18 March 2010

View article titled, Hyperglycemia-Induced Platelet Activation in Type 2 Diabetes Is Resistant to Aspirin but Not to a Nitric Oxide–Donating Agent

Includes: Supplementary data

Journal Articles

Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes: A double-blind, randomized, crossover study

Francesca Porcellati, MD, Paolo Rossetti, MD, Natalia Ricci Busciantella, MD, Stefania Marzotti, MD, Paola Lucidi, MD, Steven Luzio, MD, David R. Owens, MD, Geremia B. Bolli, MD, Carmine G. Fanelli, MD

Diabetes Care 2007;30(10):2447–2452

https://doi.org/10.2337/dc07-0002

Published: 01 October 2007

View article titled, Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes: <subtitle>A double-blind, randomized, crossover study</subtitle>

Includes: Supplementary data

Journal Articles

Make Your Diabetic Patients Walk: Long-term impact of different amounts of physical activity on type 2 diabetes

Chiara Di Loreto, MD, Carmine Fanelli, MD, Paola Lucidi, MD, Giuseppe Murdolo, MD, Arianna De Cicco, MD, Natascia Parlanti, MD, Anna Ranchelli, MD, Cristina Fatone, MD, Chiara Taglioni, MD, Fausto Santeusanio, MD, Pierpaolo De Feo, MD

Diabetes Care 2005;28(6):1295–1302

https://doi.org/10.2337/diacare.28.6.1295

Published: 01 June 2005

View article titled, Make Your Diabetic Patients Walk: <subtitle>Long-term impact of different amounts of physical activity on type 2 diabetes</subtitle>

Journal Articles

Validation of a Counseling Strategy to Promote the Adoption and the Maintenance of Physical Activity by Type 2 Diabetic Subjects

Chiara Di Loreto, MD, Carmine Fanelli, MD, Paola Lucidi, MD, Giuseppe Murdolo, MD, Arianna De Cicco, MD, Natascia Parlanti, MD, Fausto Santeusanio, MD, Paolo Brunetti, MD, Pierpaolo De Feo, MD

Diabetes Care 2003;26(2):404–408

https://doi.org/10.2337/diacare.26.2.404

Published: 01 February 2003

View article titled, Validation of a Counseling Strategy to Promote the Adoption and the Maintenance of Physical Activity by Type 2 Diabetic Subjects

NARROW

Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128–2136

Pharmacokinetic and Pharmacodynamic Head-to-Head Comparison of Clinical, Equivalent Doses of Insulin Glargine 300 units · mL⁻¹ and Insulin Degludec 100 units · mL⁻¹ in Type 1 Diabetes

Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes

How to Accurately Establish Pharmacokinetics/Pharmacodynamics of Long-Acting Insulins in Humans: Relevance to Biosimilar Insulins

Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection

Low Levels of Unmodified Insulin Glargine in Plasma of People With Type 2 Diabetes Requiring High Doses of Basal Insulin

Pharmacokinetics and Pharmacodynamics of Insulin Glargine Given in the Evening as Compared With in the Morning in Type 2 Diabetes

Thirty Years of Research on the Dawn Phenomenon: Lessons to Optimize Blood Glucose Control in Diabetes

Metabolism of Insulin Glargine After Repeated Daily Subcutaneous Injections in Subjects With Type 2 Diabetes

Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes Mellitus

Pharmacokinetics and Pharmacodynamics of Therapeutic Doses of Basal Insulins NPH, Glargine, and Detemir After 1 Week of Daily Administration at Bedtime in Type 2 Diabetic Subjects: A randomized cross-over study

Pivotal Role of Timely Basal Insulin Replacement After Metformin Failure in Sustaining Long-Term Blood Glucose Control at a Target in Type 2 Diabetes

Hyperglycemia-Induced Platelet Activation in Type 2 Diabetes Is Resistant to Aspirin but Not to a Nitric Oxide–Donating Agent

Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes: A double-blind, randomized, crossover study

Make Your Diabetic Patients Walk: Long-term impact of different amounts of physical activity on type 2 diabetes

Validation of a Counseling Strategy to Promote the Adoption and the Maintenance of Physical Activity by Type 2 Diabetic Subjects

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

This Feature Is Available To Subscribers Only